Miller Fisher syndrome: Brief overview and update with a focus on electrophysiological findings

European Journal of Neurology

Volumn 19, Issue 1, 2012, Pages

  Aranyi Z ^a   Kovacs T ^a   Sipos, I ^a   Bereczki, D ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Cerebrospinal fluid; Clinical signs; Electrophysiology; Miller Fisher syndrome; Pathology; Prognosis

Indexed keywords

ADALIMUMAB; GANGLIOSIDE GQ 1B ANTIBODY; IMMUNOGLOBULIN; INFLIXIMAB; INFLUENZA VACCINE; STAVUDINE;

BURKITT LYMPHOMA; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHRONIC LYMPHATIC LEUKEMIA; CONTRAST ENHANCEMENT; DEMYELINATION; ELECTROPHYSIOLOGY; ESCHERICHIA COLI INFECTION; GUILLAIN BARRE SYNDROME; HODGKIN DISEASE; HUMAN; LUNG CANCER; MORBIDITY; MOTOR NERVE CONDUCTION; NERVE POTENTIAL; NERVE ROOT; NEUROIMAGING; NEUROMUSCULAR SYNAPSE; OPHTHALMOPLEGIA; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SENSORY NERVE; SENSORY NERVE CONDUCTION; WAVEFORM;

HUMANS; MILLER FISHER SYNDROME;

EID: 84155168002     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03445.x     Document Type: Review

References (108)

1. Landry O. Note sur la paralysie ascendante aigue. Gazette Hebdomadaire de Medicin 1859; 6: 472-474. 486-488.
2. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-nevrite hyperalbuminose du liquide cephalorachidien sans reaction cellulaire. Bull Soc Med Hop Paris 1916; 40: 1462-1470.
3. Collier J. Peripheral neuritis. Edinburgh Med J 1932; 39: 601-618.
4. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255: 57-65.
5. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986; 43: 1150-1152.
6. Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol 1994; 51: 671-675.
7. Shuaib A, Becker WJ. Variants of Guillain-Barré syndrome: Miller Fisher syndrome, facial diplegia and multiple cranial nerve palsies. Can J Neurol Sci 1987; 14: 611-616.
8. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiol 2009; 32: 150-163.
9. Lo YL. Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve 2007; 36: 615-627.
10. Yuan CL, Wang YJ, Tsai CP. Miller Fisher syndrome: a hospital-based retrospective study. Eur Neurol 2000; 44: 79-85.
11. Ma YM, Liu TK, Wong V. Guillain-Barre syndrome in southern Chinese children: 32year experience in Hong Kong. Pediatr Int 2010; 52: 13-19.
12. Lolekha P, Phanthumchinda K. Miller-Fisher syndrome at king Chulalongkorn memorial hospital. J Med Assoc Thai 2009; 92: 471-477.
13. Rodríguez Uranga JJ, Delgado López F, Franco Macías E, Sánchez Arjona MB, Martínez Quesada C, Palomino García A. Miller-Fisher syndrome: clinical features, associated infections and clinical course in 8 cases. Med Clin (Barc) 2004; 122: 223-226.
14. Téllez-Zenteno JF, Jacinto-Tinajero JC, Avila-Funes A, García-Ramos G, Negrete-Pulido O, Sentíes-Madrid H. Guillain-Barre syndrome. Experience in a third level hospital. Rev Invest Clin 2001; 53: 311-314.
15. Buompadre MC, Gáñez LA, Miranda M, Arroyo HA. Unusual variants of Guillain-Barré syndrome in infancy. Rev Neurol 2006; 42: 85-90.
16. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Guillain-Barré syndrome variants in Emilia-Romagna, Italy, 1992-3: incidence, clinical features, and prognosis. J Neurol Neurosurg Psychiatry 1998; 65: 218-224.
17. Bogliun G, Beghi E; Italian GBS Registry Study Group. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004; 110: 100-106.
18. Guarino M, Stracciari A, Cirignotta F, D'Alessandro R, Pazzaglia P. Neoplastic meningitis presenting with ophthalmoplegia, ataxia, and areflexia (Miller Fisher syndrome). Arch Neurol 1995; 52: 443-444.
19. Roquer J, Pou Serradell A. Paraneoplastic Miller Fisher syndrome? Neurologia 1992; 7: 40.
20. Csépány T, Boczán J, Magyar MT, et al. Miller Fisher syndrome - a presenting clinical manifestation of lung cancer in a previously apparently healthy individual. J Neurol 2004; 251: 898-900.
21. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992; 31: 677-679.
22. Willison HJ, Halstead SK, Beveridge E, et al. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome. J Neuroimmunol 2008; 202: 172-182.
23. Mizoguchi K. Anti-GQ1b IgG antibody activities related to the severity of Miller Fisher syndrome. Neurol Res 1998; 20: 617-624.
24. Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 2004; 148: 200-205.
25. Wessig C, Buchwald B, Toyka KV, Martini R. Miller Fisher syndrome: immunofluorescence and immunoelectron microscopic localization of IgG at the mouse neuromuscular junction. Acta Neuropathol 2001; 101: 239-244.
26. Liu JX, Willison HJ, Pedrosa-Domeliof F. Immunolocalisation of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009; 50: 3226-3232.
27. Plomp JJ, Molenaar PC, O'Hanlon GM, et al. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol 1999; 45: 189-199.
28. Lo YL, Chan LL, Pan A, Ratnagopal P. Acute ophthalmoplegia in the anti-GQ1b antibody syndrome: electrophysiological evidence of neuromuscular transmission defect in the orbicularis oculi. J Neurol Neurosurg Psychiatry 2004; 75: 436-440.
29. Yuki N, Taki T, Takahashi M, et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994; 36: 791-793.
30. Suzuki T, Chiba A, Kusunoki S, Chikuda M, Fujita T, Miso K. Anti-GQ1b ganglioside antibody and ophthalmoplegia of undetermined cause. Br J Ophthalmol 1998; 82: 916-918.
31. Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004; 25: 61-66.
32. Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmune 2009; 215: 1-9.
33. Tüzün E, Kürtüncü M, Lang B, et al. Bickerstaff's encephalitis and Miller Fisher syndrome associated with voltage-gated potassium channel and novel anti-neuronal antibodies. Eur J Neurol 2010; 17: 1304-1307.
34. Kurmann PT, Van Linthoudt D, So AK. Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol 2009; 28: 93-94.
35. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006; 54: 1429-1434.
36. Shah SS, Rodriguez T, McGowan JP. Miller Fisher variant of Guillain-Barré syndrome associated with lactic acidosis and stavudine therapy. Clin Infect Dis 2003; 36: e131-e133.
37. Blanco-Marchite CI, Buznego-Suárez L, Fagúndez-Vargas MA, Méndez-Llatas M, Pozo-Martos P. Miller Fisher syndrome, internal and external ophthalmoplegia after flu vaccination. Arch Soc Esp Oftalmol 2008; 83: 433-435.
38. Thaler A. Miller Fisher syndrome in a 66-year-old female after flu and pneumovax vaccinations. J Am Med Dir Assoc 2008; 9: 283-284.
39. Gentile S, Messina M, Rainero I, Lo Giudice R, De Martino P, Pinessi L. Miller Fisher syndrome associated with Burkitt's lymphoma. Eur J Neurol 2006; 13: 430.
40. Rubio-Nazabal E, Marey-Lopez J, Torres-Carrete JP, Alvarez-Perez P, Rey Del Corral P. Miller-Fisher syndrome and Hodgkin's disease. J Neurol Neurosurg Psychiatry 2002; 73: 344.
41. Aki Z, Aksoy O, Sucak G, Kuruoǧlu R, Yaǧci M. Miller-Fisher syndrome associated with chronic lymphocytic leukemia. Neurol India 2008; 56: 198-200.
42. Nakatsuji Y, Sadahiro S, Watanabe S, et al. Leptomeningeal signet-ring cell carcinomatosis presenting with ophthalmoplegia, areflexia and ataxia. Clin Neuropathol 2001; 20: 272-275.
43. Blasetti A, Cerruto M, Cutarella R, et al. Miller Fisher syndrome and Escherichia coli infection: is it a novel association? J Child Neurol 2007; 22: 71-73.
44. Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997; 63: 494-500.
45. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001; 56: 1104-1106.
46. Kollár K, Liptai Z, Rosdy B, Móser J. Guillain-Barré syndrome in childhood. Ideggyogy Sz 2009; 62: 399-404.
47. Sauron B, Bouche P, Cathala HP, Chain F, Castaigne P. Miller Fisher syndrome: clinical and electrophysiologic evidence of peripheral origin in 10 cases. Neurology 1984; 34: 953-956.
48. Bae JS, Kim JK, Kim SH, Kim OK. Bilateral internal ophthalmoplegia as an initial sole manifestation of Miller Fisher syndrome. J Clin Neurosci 2009; 16: 963-964.
49. Smith J, Clarke L, Severn P, Boyce R. Unilateral external ophthalmoplegia in Miller Fisher syndrome: case report. BMC Ophthalmol 2007; 7: 7.
50. Wertheim MS, Benzimra JD, Jadresic LP, Ferris JD. Ocular presentation of pediatric Miller-Fisher syndrome. J Pediatr Ophthalmol Strabismus 2008; 45: 245-246.
51. Fleury V, Aqallal A, Lagrange E, Besson G, Caudie C. Acute bilateral mydriasis associated with anti-GQ1b antibody. J Clin Neurosci 2010; 17: 514-515.
52. Jindal G, Parmar VR, Gupta VK. Isolated ptosis as acute ophthalmoplegia without ataxia, positive for anti-GQ1b immunoglobulin G. Pediatr Neurol 2009; 41: 451-452.
53. Oguro H, Yamaguchi S, Abe S, Bokura H, Kobayashi S. Acute divergence paralysis in the Miller Fisher syndrome. Rinsho Shinkeigaku 2005; 45: 524-526.
54. Abdul-Rahman AM, Raj R. Eyelid nystagmus in Miller Fisher syndrome. Br J Ophthalmol 2008; 92: 1576.
55. Chan JW. Optic neuritis in anti-GQ1b positive recurrent Miller Fisher syndrome. Br J Ophthalmol 2003; 87: 1185-1186.
56. Lolekha P, Phanthumchinda K. Optic neuritis in a patient with Miller-Fisher syndrome. J Med Assoc Thai 2008; 91: 1909-1913.
57. Robbins MS, Roth S, Swerdlow ML, Bieri P, Herskovitz S. Optic neuritis and palatal dysarthria as presenting features of post-infectious GQ1b antibody syndrome. Clin Neurol Neurosurg 2009; 111: 465-466.
58. Howell RJ, Davolos AG, Clary MS, Frake PC, Joshi AS, Chaboki H. Miller fisher syndrome presents as an acute voice change to hypernasal speech. Laryngoscope 2010; 120: 978-980.
59. Lau KK, Goh KJ, Lee HC, Chan YT, Tan CT. The co-occurrence of serologically proven myasthenia gravis and Miller Fisher/Guillain Barré overlap syndrome: a case report. J Neurol Sci 2009; 276: 187-188.
60. Mak W, Chan KH, Ho SL. A case of ocular myasthenia gravis and Miller-Fisher syndrome. Hosp Med 2005; 66: 116-117.
61. Friedman DI, Potts E. Headache associated with miller fisher syndrome. Headache 2007; 47: 1347-1348.
62. Becker WJ, Watters GV, Humphreys P. Fisher syndrome in childhood. Neurology 1981; 31: 555-560.
63. Segurado OG, Krüger H, Mertens HG. Clinical significance of serum and CSF findings in the Guillain-Barré syndrome and related disorders. J Neurol 1986; 233: 202-208.
64. Chiba S, Sigiyama T, Yonekura K, et al. An antibody to VacA Helicobacter pylori int he CSF of patients with Miller Fisher syndrome. Neurology 2004; 63: 2184-2186.
65. Chiang HL, Lyu RK, Tseng MY, et al. Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Clin Chim Acta 2009; 405: 143-147.
66. Huang YC, Lyu RK, Tseng MY, et al. Decreased intrathecal synthesis of prostaglandin D2 synthase in the cerebrospinal fluid of patients with acute inflammatory demyelinating polyneuropathy. J Neuroimmunol 2009; 206: 100-105.
67. Seki H, Tsukamoto T, Aso H, Tamura K. Intrathecal synthesis of immunosuppressive acidic protein (IAP) in patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci 1988; 85: 259-266.
68. Sato S, Suzuki K, Nagao R, et al. Detection of MCP-1 and IL-8 in the serum and cerebrospinal fluid of a child with Miller Fisher syndrome. J Clin Neurosci 2009; 16: 1698-1699.
69. Ito M, Kuwabara S, Odaka M, et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008; 255: 674-682.
70. Nagaoka U, Kato T, Kurita K, et al. Cranial nerve enhancement on three-dimensional MRI in Miller Fisher syndrome. Neurology 1996; 47: 1601-1602.
71. Hattori M, Takada K, Yamada K, Kamimoto K, Mitake S. A case of Miller Fisher syndrome with gadolinium-enhancing lesions in the cranial nerves and the cauda equina on magnetic resonance imaging. Rinsho Shinkeigaku 1999; 39: 1054-1058.
72. Inoue N, Ichimura H, Goto S, Hashimoto Y, Ushio Y. MR imaging findings of spinal posterior column involvement in a case of Miller Fisher syndrome. AJNR Am J Neuroradiol 2004; 25: 645-648.
73. Kiphuth IC, Saake M, Lunkenheimer J, Dörfler A, Schwab S, Kollmar R. Bilateral enhancement of the cranial nerves III-XII in severe Miller-Fisher syndrome. Eur Neurol 2009; 62: 252-253.
74. Kim YK, Kim JS, Jeong SH, Park KS, Kim SE, Park SH. Cerebral glucose metabolism in Fisher syndrome. J Neurol Neurosurg Psychiatry 2009; 80: 512-517.
75. Philips MS, Stewart S, Anderson JR. Neuropathological findings in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 1984; 47: 492-495.
76. Barontini F, Di Lollo S, Mauri S, Lambruschini P. Localization of the pathological process in Miller Fisher syndrome. Ital J Neurol Sci 1992; 13: 221-225.
77. Ropper A. Absence of CNS lesion in autopsied patients with Miller-Fisher syndrome. Arch Neurol 1985; 42: 15.
78. Meienberg O. Lesion site in Fisher's syndrome. Arch Neurol 1984; 41: 250-251.
79. Kornberg AJ, Pestronk A, Blume GM, Lopate G, Yue J, Hahn A. Selective staining of the cerebellar molecular layer by serum IgG in Miller-Fisher and related syndromes. Neurology 1996; 47: 1317-1320.
80. Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 1999; 22: 1071-1074.
81. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003; 126: 2279-2290.
82. Yuki N, Susuki K, Hirata K. Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: relation to Miller-Fisher syndrome. Neurology 2000; 54: 1851-1853.
83. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70: 50-55.
84. Lee SH, Lim GH, Kim JS, et al. Acute ophthalmoplegia (without ataxia) associated with anti-GQ1b antibody. Neurology 2008; 71: 426-429.
85. Jamal GA, Ballantyne JP. The localization of the lesion in patients with acute ophthalmoplegia, ataxia and areflexia (Miller Fisher syndrome). A serial multimodal neurophysiological study. Brain 1988; 111: 95-114.
86. Fross RD, Daube JR. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology 1987; 37: 1493-1498.
87. Arányi Z, Szabó G, Szepesi B, Folyovich A. Proximal conduction abnormality of the facial nerve in Miller Fisher syndrome: a study using transcranial magnetic stimulation. Clin Neurophysiol 2006; 117: 821-827.
88. Ogawara K, Kuwabara S, Yuki N. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b antibody syndrome involving both the peripheral and the central nervous systems Muscle Nerve 2002; 26: 845-849.
89. Kuwabara S, Asahina M, Nakajima M, et al. Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Ann Neurol 1999; 45: 533-536.
90. de Pablos C, Calleja J, Fernandez F, Berciano J. Miller Fisher syndrome: an electrophysiologic case study. Electromyogr Clin Neurophysiol 1988; 28: 21-25.
91. Dachy B, Deltenre P, Deconinck N, Dan B. The H reflex as a diagnostic tool for Miller Fisher syndrome in pediatric patients. J Clin Neurosci 2010; 17: 410-411.
92. Ropper AH, Shahani B. Proposed mechanism of ataxia in Fisher's syndrome. Arch Neurol 1983; 40: 397-398.
93. Willison HJ, Veitch J, Paterson G, Kennedy PG. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993; 56: 204-206.
94. Lo YL, Leoh TH, Dan YF, et al. Presynaptic neuromuscular transmission defect in the Miller Fisher syndrome. Neurology 2006; 66: 148-149.
95. Silverstein MP, Zimnowodzki S, Rucker JC. Neuromuscular junction dysfunction in Miller Fisher syndrome. Semin Ophthalmol 2008; 23: 211-213.
96. Kuwabara S, Misawa S, Takahashi H, et al. Anti-GQ1b antibody does not affect neuromuscular transmission in human limb muscles. J Neuroimmune 2007; 189: 158-162.
97. Lange DJ, DeAngelis T, Sivak MA. Single-fiber electromyography shows terminal axon dysfunction in Miller Fisher syndrome: a case report. Muscle Nerve 2006; 34: 232-234.
98. Lo YL, Ratnagopal P. Cortico-hypoglossal and corticospinal conduction abnormality in Bickerstaff's brainstem encephalitis. Clin Neurol Neurosurg 2007; 109: 523-525.
99. Lo YL, Ratnagopal P. Transcranial magnetic stimulation studies in the Miller Fisher syndrome: evidence of corticospinal tract abnormality. J Neurol Neurosurg Psychiatry 2001; 71: 210-214.
100. Lo YL, Fook-Chong S, Chan LL, Ong WY, Ratnagopal P. Electrophysiological evidence of cerebellar fiber system involvement in the Miller Fisher syndrome. J Neurol Sci 2010; 288: 49-53.
101. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005; 366: 1653-1666.
102. Lehmann HC, Hartung H-P, Hetzel GR, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders. Part 2 treatment of neuromuscular disorders. Arch Neurol 2006; 63: 1066-1071.
103. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007; 68: 1144-1146.
104. San-Juan OD, Martínez-Herrera JF, García JM, Gonzalez-Aragon MF, Del Castillo-Calcáneo Jde D, Pérez-Neri I. Miller Fisher syndrome: 10years' experience in a third-level center. Eur Neurol 2009; 62: 149-154.
105. Halstead SK, Humphreys PD, Zitman FM, Hamer J, Plomp JJ, Willison HJ. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J Peripher Nerv Syst 2008; 13: 228-235.
106. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008; 131: 1197-1208.
107. Lehmann HC, Hartung HP. Complementing the therapeutic armamentarium for Miller Fisher syndrome and related immune neuropathies. Brain 2008; 131: 1168-1170.
108. Berlit P, Rakicky J. The Miller Fisher syndrome. Review of the literature. J Clin Neuroophthalmol 1992; 12: 57-63.